Please upgrade your browser.
In yet another blow to Big Pharma, the Delhi Patent Office has revoked a patent granted in 2007 to US drugmaker Pfizer for sunitinib (brand name Sutent), a drug used to treat a type of kidney cancer, which had global sales of $1.19 billion in 2011.
A study highlights the link between poor diet and the killer disease and confirms that certain vegetables have the power to heal the bodyâs cells.
New trial results on pazopanib and temsirolimus have important implications for patients.
Several recent studies underscore how critically important it is for those fighting illness to learn how to combat stress.
German scientists test a new vaccine.
After independent data review, patients on pazopanib achieved a median progression-free survival of 8.4 months compared with 9.5 months for patients on sunitinib â a nonsignificant difference that fell within the prespecified statistical bounds for achieving non-inferiority, according to Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center in New York City.
When the NHS refused life-saving drugs to countless cancer patients, there was one woman who wouldn't take no for an answer
When youâre told âYou have cancerâ, it can seem the most shattering news you could possibly receive. But many patients are then told something infinitely worse: âThere is a treatment â but we canât afford to give it to you.
The first renal cell carcinoma (RCC) patients have been treated with an RCC-specific therapeutic vaccine in early-stage clinical trials.
New results released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna may have important implications for patients.
Results from a Phase I/II trial of the investigational compound lenvatinib (E7080), a multi-targeted, kinase inhibitor, in people with advanced hepatocellular cancer have been presented at the ESMO 2012 Congress (European Society for Medical Oncology) taking place on Friday 28 September - Tuesday 2 October. Two other studies were presented, reporting the results of lenvatinib in the treatment of recurrent glioblastoma (the most common type of brain cancer which is almost universally fatal) and lenvatinib in combination with everolimus in metastatic renal cell carcinoma.
|NeonCRM by Neon One|